세계의 의약품 재이용용 AI 시장 : 시장 규모, 점유율 및 동향 분석 - 컴포넌트별, 기술별, 최종 용도별, 용도별, 지역별 전망 및 장래 예측(2025-2032년)

The Global AI In Drug Repurposing Market size is expected to reach $4.11 billion by 2032, rising at a market growth of 19.7% CAGR during the forecast period.

Key Highlights:

• The North America market dominated Global AI In Drug Repurposing Market in 2024, accounting for a 42.30% revenue share in 2024.
• The U.S. market is projected to maintain its leadership in North America, reaching a market size of USD 1.31 billion by 2032.
• Among the Component, the Software & Platform segment dominated the global market, contributing a revenue share of 64.95% in 2024.
• In terms of Technology, Machine Learning/Deep Learning segment are expected to lead the global market, with a projected revenue share of 40.63% by 2032.
• The Pharmaceutical & BioTechnology Companies market emerged as the leading End Use in 2024, capturing a 58.41% revenue share, and is projected to retain its dominance during the forecast period.
• The Oncology Market in Application is poised to grow at the market in 2032 with a market size of USD 1.28 billion and is projected to maintain its dominant position throughout the forecast period.

The pharmaceutical sector is experiencing a transformative shift as AI revolutionizes drug repurposing-identifying new therapeutic uses for existing compounds. Drug repurposing has developed into a systematic and data-driven approach powered by deep learning, graph-based models, and machine learning. By deploying vast biomedical datasets-including proteomics, clinical records, and genomics, AI now unveils complex drug-disease relationships that were not evident previously. This development has shifted AI-based repurposing from an experimental idea to a mainstream R&D strategy, supported by a strong partnership between technology providers and pharmaceutical companies. AI allows more efficient lifecycle management, enhanced targeting of unmet medical requirements, and faster drug discovery timelines.

The AI in Drug Repurposing market is anticipated to grow, driven by numerous trends. Repurposing is expanding into rescue programs and rare diseases for previously failed molecules, offering strategic as well as humanitarian advantages. Adaptive learning systems now allow continued model updates as new data emerges, improving long-term value and accuracy. Also, AI systems largely manage multimodal data and focus on explainability, providing mechanistic insights that clinical trust and build regulatory confidence. Market players deploy vertical partnerships, hybrid business models, and scalable AI platforms to support innovation. The market is witnessing intensive competition as the landscape is predicted to consolidate around a few integrated AI bio-ecosystems connected to pharma pipelines, with players emphasizing on rare conditions or specific therapeutic.

COVID 19 Impact Analysis

The COVID-19 pandemic sped up the use of AI in drug repurposing a lot, showing how important it is for pharmaceutical R&D. Organizations used AI to quickly screen existing compounds because they needed treatments right away. This cut the time it took to find new drugs from years to weeks. AI models were able to make better predictions because there was more data available on SARS-CoV-2. Preliminary success stories also made investors and the industry more confident. Public-private partnerships and collaborative data-sharing projects added to AI datasets, which led to new ideas for hybrid modeling approaches. As a result, AI repurposing went from being a test project to a key part of modern drug development, showing how it could change things even after the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.

Technology Outlook

Based on Technology, the market is segmented into Machine Learning/Deep Learning, Natural Language Processing (NLP), Knowledge Graphs & Network-Based AI, Generative AI & Large Language Models (LLMs), and Computer Vision. The natural language processing (NLP) segment witnessed 20% revenue share in the AI In drug repurposing market in 2024. Natural language processing plays a vital role in extracting insights from unstructured biomedical information such as research papers, patents, and clinical trial reports. NLP algorithms can scan millions of documents to identify potential drug-target or drug-disease connections by interpreting scientific language contextually.

End Use Outlook

Based on End Use, the market is segmented into Pharmaceutical & BioTechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, and Other End Use. The contract research organizations (CROs) segment recorded 20% revenue share in the AI In drug repurposing market in 2024. Contract research organizations are increasingly adopting AI-based platforms for drug repurposing to support pharmaceutical clients with data processing, clinical insights, and experimental validation. CROs use AI tools to design efficient trial protocols, identify drug candidates with repurposing potential, and model patient responses.

Regional Outlook

Region-wise, the AI In Drug Repurposing Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded 42% revenue share in the AI In Drug Repurposing Market in 2024. The AI in Drug Repurposing market is anticipated to grow at a significant rate in North America and Europe. This is due to large investment in pharma R&D, well-established ecosystem of AI startups collaborating CROs and big pharma, and extensive biomedical datasets (real-world evidence, EHRs, and genomics). Furthermore, the European market has strong translational research networks, well-established biotech and pharmaceutical clusters, and growing regulatory interest in AI-based tools, resulting in strong demand. Also, Europe focuses on data privacy deployments and regulatory alignment, which result in surging clinical validation of repurposing candidates.

In the Asia Pacific and LAMEA regions, the AI in Drug Repurposing market is expected to experience substantial expansion. This is driven by rapidly growing R&D spending in India, South Korea, and China, regional health/AI initiatives, rising biomedical data availability, and numerous partnerships between global pharma and regional AI providers. Moreover, the LAMEA region is also witnessing growth due to the rising clinical trial activity and increasing government digital health programs. The global collaborations and private investments target region-specific demands, particularly in nations with strong healthcare infrastructure.

List of Key Companies Profiled

• Ginkgo Bioworks Holdings, Inc.
• IBM Corporation
• Atomwise, Inc.
• Cyclica, Inc.
• Genesis Healthcare Co.
• Verge, Inc.
• Novartis AG
• Schrodinger, Inc
• Recursion Pharmaceuticals, Inc.
• The Cradle Company

Global AI In Drug Repurposing Market Report Segmentation

By Component

• Software & Platform
• Services

By Technology

• Machine Learning/Deep Learning
• Natural Language Processing (NLP)
• Knowledge Graphs & Network-Based AI
• Generative AI & Large Language Models (LLMs)
• Computer Vision

By End Use

• Pharmaceutical & BioTechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Other End Use

By Application

• Oncology
• Neurology
• Infectious Diseases
• Rare & Orphan Diseases
• Cardiology
• Other Application

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global AI In Drug Repurposing Market, by Component
  • 1.4.2 Global AI In Drug Repurposing Market, by Technology
  • 1.4.3 Global AI In Drug Repurposing Market, by End Use
  • 1.4.4 Global AI In Drug Repurposing Market, by Application
  • 1.4.5 Global AI In Drug Repurposing Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Market Trends - AI In Drug Repurposing Market

Chapter 5. State of Competition - AI In Drug Repurposing Market

Chapter 6. Value Chain Analysis of AI In Drug Repurposing Market

Chapter 7. Product Life Cycle - AI In Drug Repurposing Market

Chapter 8. Market Consolidation - AI In Drug Repurposing Market

Chapter 9. Key Customer Criteria - AI In Drug Repurposing Market

Chapter 10. Global AI In Drug Repurposing Market by Component

• 10.1 Global Software & Platform Market by Region
• 10.2 Global Services Market by Region

Chapter 11. Global AI In Drug Repurposing Market by Technology

• 11.1 Global Machine Learning/Deep Learning Market by Region
• 11.2 Global Natural Language Processing (NLP) Market by Region
• 11.3 Global Knowledge Graphs & Network-Based AI Market by Region
• 11.4 Global Generative AI & Large Language Models (LLMs) Market by Region
• 11.5 Global Computer Vision Market by Region

Chapter 12. Global AI In Drug Repurposing Market by End Use

• 12.1 Global Pharmaceutical & BioTechnology Companies Market by Region
• 12.2 Global Contract Research Organizations (CROs) Market by Region
• 12.3 Global Academic & Research Institutes Market by Region
• 12.4 Global Other End Use Market by Region

Chapter 13. Global AI In Drug Repurposing Market by Application

• 13.1 Global Oncology Market by Region
• 13.2 Global Neurology Market by Region
• 13.3 Global Infectious Diseases Market by Region
• 13.4 Global Rare & Orphan Diseases Market by Region
• 13.5 Global Cardiology Market by Region
• 13.6 Global Other Application Market by Region

Chapter 14. Global AI In Drug Repurposing Market by Region

• 14.1 North America AI In Drug Repurposing Market
• 14.2 Key Factors Impacting the Market
  • 14.2.1 Market Drivers
  • 14.2.2 Market Restraints
  • 14.2.3 Market Opportunities
  • 14.2.4 Market Challenges
  • 14.2.5 Market Trends - North America AI In Drug Repurposing Market
  • 14.2.6 State of Competition - North American AI in Drug Repurposing Market
  • 14.2.7 North America AI In Drug Repurposing Market by Component
    • 14.2.7.1 North America Software & Platform Market by Country
    • 14.2.7.2 North America Services Market by Country
  • 14.2.8 North America AI In Drug Repurposing Market by Technology
    • 14.2.8.1 North America Machine Learning/Deep Learning Market by Region
    • 14.2.8.2 North America Natural Language Processing (NLP) Market by Region
    • 14.2.8.3 North America Knowledge Graphs & Network-Based AI Market by Region
    • 14.2.8.4 North America Generative AI & Large Language Models (LLMs) Market by Region
    • 14.2.8.5 North America Computer Vision Market by Region
  • 14.2.9 North America AI In Drug Repurposing Market by End Use
    • 14.2.9.1 North America Pharmaceutical & BioTechnology Companies Market by Country
    • 14.2.9.2 North America Contract Research Organizations (CROs) Market by Country
    • 14.2.9.3 North America Academic & Research Institutes Market by Country
    • 14.2.9.4 North America Other End Use Market by Country
  • 14.2.10 North America AI In Drug Repurposing Market by Application
    • 14.2.10.1 North America Oncology Market by Country
    • 14.2.10.2 North America Neurology Market by Country
    • 14.2.10.3 North America Infectious Diseases Market by Country
    • 14.2.10.4 North America Rare & Orphan Diseases Market by Country
    • 14.2.10.5 North America Cardiology Market by Country
    • 14.2.10.6 North America Other Application Market by Country
  • 14.2.11 North America AI In Drug Repurposing Market by Country
    • 14.2.11.1 US AI In Drug Repurposing Market
      • 14.2.11.1.1 US AI In Drug Repurposing Market by Component
      • 14.2.11.1.2 US AI In Drug Repurposing Market by Technology
      • 14.2.11.1.3 US AI In Drug Repurposing Market by End Use
      • 14.2.11.1.4 US AI In Drug Repurposing Market by Application
    • 14.2.11.2 Canada AI In Drug Repurposing Market
      • 14.2.11.2.1 Canada AI In Drug Repurposing Market by Component
      • 14.2.11.2.2 Canada AI In Drug Repurposing Market by Technology
      • 14.2.11.2.3 Canada AI In Drug Repurposing Market by End Use
      • 14.2.11.2.4 Canada AI In Drug Repurposing Market by Application
    • 14.2.11.3 Mexico AI In Drug Repurposing Market
      • 14.2.11.3.1 Mexico AI In Drug Repurposing Market by Component
      • 14.2.11.3.2 Mexico AI In Drug Repurposing Market by Technology
      • 14.2.11.3.3 Mexico AI In Drug Repurposing Market by End Use
      • 14.2.11.3.4 Mexico AI In Drug Repurposing Market by Application
    • 14.2.11.4 Rest of North America AI In Drug Repurposing Market
      • 14.2.11.4.1 Rest of North America AI In Drug Repurposing Market by Component
      • 14.2.11.4.2 Rest of North America AI In Drug Repurposing Market by Technology
      • 14.2.11.4.3 Rest of North America AI In Drug Repurposing Market by End Use
      • 14.2.11.4.4 Rest of North America AI In Drug Repurposing Market by Application
• 14.3 Europe AI In Drug Repurposing Market
• 14.4 Key Factors Impacting the Market
  • 14.4.1 Market Drivers
  • 14.4.2 Market Restraints
  • 14.4.3 Market Opportunities
  • 14.4.4 Market Challenges
  • 14.4.5 Market Trends - Europe AI In Drug Repurposing Market
  • 14.4.6 State of Competition - Europe AI in Drug Repurposing market
  • 14.4.7 Europe AI In Drug Repurposing Market by Component
    • 14.4.7.1 Europe Software & Platform Market by Country
    • 14.4.7.2 Europe Services Market by Country
  • 14.4.8 Europe AI In Drug Repurposing Market by Technology
    • 14.4.8.1 Europe Machine Learning/Deep Learning Market by Country
    • 14.4.8.2 Europe Natural Language Processing (NLP) Market by Country
    • 14.4.8.3 Europe Knowledge Graphs & Network-Based AI Market by Country
    • 14.4.8.4 Europe Generative AI & Large Language Models (LLMs) Market by Country
    • 14.4.8.5 Europe Computer Vision Market by Country
  • 14.4.9 Europe AI In Drug Repurposing Market by End Use
    • 14.4.9.1 Europe Pharmaceutical & BioTechnology Companies Market by Country
    • 14.4.9.2 Europe Contract Research Organizations (CROs) Market by Country
    • 14.4.9.3 Europe Academic & Research Institutes Market by Country
    • 14.4.9.4 Europe Other End Use Market by Country
  • 14.4.10 Europe AI In Drug Repurposing Market by Application
    • 14.4.10.1 Europe Oncology Market by Country
    • 14.4.10.2 Europe Neurology Market by Country
    • 14.4.10.3 Europe Infectious Diseases Market by Country
    • 14.4.10.4 Europe Rare & Orphan Diseases Market by Country
    • 14.4.10.5 Europe Cardiology Market by Country
    • 14.4.10.6 Europe Other Application Market by Country
  • 14.4.11 Europe AI In Drug Repurposing Market by Country
    • 14.4.11.1 Germany AI In Drug Repurposing Market
      • 14.4.11.1.1 Germany AI In Drug Repurposing Market by Component
      • 14.4.11.1.2 Germany AI In Drug Repurposing Market by Technology
      • 14.4.11.1.3 Germany AI In Drug Repurposing Market by End Use
      • 14.4.11.1.4 Germany AI In Drug Repurposing Market by Application
    • 14.4.11.2 UK AI In Drug Repurposing Market
      • 14.4.11.2.1 UK AI In Drug Repurposing Market by Component
      • 14.4.11.2.2 UK AI In Drug Repurposing Market by Technology
      • 14.4.11.2.3 UK AI In Drug Repurposing Market by End Use
      • 14.4.11.2.4 UK AI In Drug Repurposing Market by Application
    • 14.4.11.3 France AI In Drug Repurposing Market
      • 14.4.11.3.1 France AI In Drug Repurposing Market by Component
      • 14.4.11.3.2 France AI In Drug Repurposing Market by Technology
      • 14.4.11.3.3 France AI In Drug Repurposing Market by End Use
      • 14.4.11.3.4 France AI In Drug Repurposing Market by Application
    • 14.4.11.4 Russia AI In Drug Repurposing Market
      • 14.4.11.4.1 Russia AI In Drug Repurposing Market by Component
      • 14.4.11.4.2 Russia AI In Drug Repurposing Market by Technology
      • 14.4.11.4.3 Russia AI In Drug Repurposing Market by End Use
      • 14.4.11.4.4 Russia AI In Drug Repurposing Market by Application
    • 14.4.11.5 Spain AI In Drug Repurposing Market
      • 14.4.11.5.1 Spain AI In Drug Repurposing Market by Component
      • 14.4.11.5.2 Spain AI In Drug Repurposing Market by Technology
      • 14.4.11.5.3 Spain AI In Drug Repurposing Market by End Use
      • 14.4.11.5.4 Spain AI In Drug Repurposing Market by Application
    • 14.4.11.6 Italy AI In Drug Repurposing Market
      • 14.4.11.6.1 Italy AI In Drug Repurposing Market by Component
      • 14.4.11.6.2 Italy AI In Drug Repurposing Market by Technology
      • 14.4.11.6.3 Italy AI In Drug Repurposing Market by End Use
      • 14.4.11.6.4 Italy AI In Drug Repurposing Market by Application
    • 14.4.11.7 Rest of Europe AI In Drug Repurposing Market
      • 14.4.11.7.1 Rest of Europe AI In Drug Repurposing Market by Component
      • 14.4.11.7.2 Rest of Europe AI In Drug Repurposing Market by Technology
      • 14.4.11.7.3 Rest of Europe AI In Drug Repurposing Market by End Use
      • 14.4.11.7.4 Rest of Europe AI In Drug Repurposing Market by Application
• 14.5 Asia Pacific AI In Drug Repurposing Market
• 14.6 Key Factors Impacting the Market
  • 14.6.1 Market Drivers
  • 14.6.2 Market Restraints
  • 14.6.3 Market Opportunities
  • 14.6.4 Market Challenges
  • 14.6.5 Market Trends - Asia Pacific AI In Drug Repurposing Market
  • 14.6.6 State of Competition - Asia Pacific AI In Drug Repurposing Market
  • 14.6.7 Asia Pacific AI In Drug Repurposing Market by Component
    • 14.6.7.1 Asia Pacific Software & Platform Market by Country
    • 14.6.7.2 Asia Pacific Services Market by Country
  • 14.6.8 Asia Pacific AI In Drug Repurposing Market by Technology
    • 14.6.8.1 Asia Pacific Machine Learning/Deep Learning Market by Country
    • 14.6.8.2 Asia Pacific Natural Language Processing (NLP) Market by Country
    • 14.6.8.3 Asia Pacific Knowledge Graphs & Network-Based AI Market by Country
    • 14.6.8.4 Asia Pacific Generative AI & Large Language Models (LLMs) Market by Country
    • 14.6.8.5 Asia Pacific Computer Vision Market by Country
  • 14.6.9 Asia Pacific AI In Drug Repurposing Market by End Use
    • 14.6.9.1 Asia Pacific Pharmaceutical & BioTechnology Companies Market by Country
    • 14.6.9.2 Asia Pacific Contract Research Organizations (CROs) Market by Country
    • 14.6.9.3 Asia Pacific Academic & Research Institutes Market by Country
    • 14.6.9.4 Asia Pacific Other End Use Market by Country
  • 14.6.10 Asia Pacific AI In Drug Repurposing Market by Application
    • 14.6.10.1 Asia Pacific Oncology Market by Country
    • 14.6.10.2 Asia Pacific Neurology Market by Country
    • 14.6.10.3 Asia Pacific Infectious Diseases Market by Country
    • 14.6.10.4 Asia Pacific Rare & Orphan Diseases Market by Country
    • 14.6.10.5 Asia Pacific Cardiology Market by Country
    • 14.6.10.6 Asia Pacific Other Application Market by Country
  • 14.6.11 Asia Pacific AI In Drug Repurposing Market by Country
    • 14.6.11.1 China AI In Drug Repurposing Market
      • 14.6.11.1.1 China AI In Drug Repurposing Market by Component
      • 14.6.11.1.2 China AI In Drug Repurposing Market by Technology
      • 14.6.11.1.3 China AI In Drug Repurposing Market by End Use
      • 14.6.11.1.4 China AI In Drug Repurposing Market by Application
    • 14.6.11.2 Japan AI In Drug Repurposing Market
      • 14.6.11.2.1 Japan AI In Drug Repurposing Market by Component
      • 14.6.11.2.2 Japan AI In Drug Repurposing Market by Technology
      • 14.6.11.2.3 Japan AI In Drug Repurposing Market by End Use
      • 14.6.11.2.4 Japan AI In Drug Repurposing Market by Application
    • 14.6.11.3 India AI In Drug Repurposing Market
      • 14.6.11.3.1 India AI In Drug Repurposing Market by Component
      • 14.6.11.3.2 India AI In Drug Repurposing Market by Technology
      • 14.6.11.3.3 India AI In Drug Repurposing Market by End Use
      • 14.6.11.3.4 India AI In Drug Repurposing Market by Application
    • 14.6.11.4 South Korea AI In Drug Repurposing Market
      • 14.6.11.4.1 South Korea AI In Drug Repurposing Market by Component
      • 14.6.11.4.2 South Korea AI In Drug Repurposing Market by Technology
      • 14.6.11.4.3 South Korea AI In Drug Repurposing Market by End Use
      • 14.6.11.4.4 South Korea AI In Drug Repurposing Market by Application
    • 14.6.11.5 Singapore AI In Drug Repurposing Market
      • 14.6.11.5.1 Singapore AI In Drug Repurposing Market by Component
      • 14.6.11.5.2 Singapore AI In Drug Repurposing Market by Technology
      • 14.6.11.5.3 Singapore AI In Drug Repurposing Market by End Use
      • 14.6.11.5.4 Singapore AI In Drug Repurposing Market by Application
    • 14.6.11.6 Malaysia AI In Drug Repurposing Market
      • 14.6.11.6.1 Malaysia AI In Drug Repurposing Market by Component
      • 14.6.11.6.2 Malaysia AI In Drug Repurposing Market by Technology
      • 14.6.11.6.3 Malaysia AI In Drug Repurposing Market by End Use
      • 14.6.11.6.4 Malaysia AI In Drug Repurposing Market by Application
    • 14.6.11.7 Rest of Asia Pacific AI In Drug Repurposing Market
      • 14.6.11.7.1 Rest of Asia Pacific AI In Drug Repurposing Market by Component
      • 14.6.11.7.2 Rest of Asia Pacific AI In Drug Repurposing Market by Technology
      • 14.6.11.7.3 Rest of Asia Pacific AI In Drug Repurposing Market by End Use
      • 14.6.11.7.4 Rest of Asia Pacific AI In Drug Repurposing Market by Application
• 14.7 LAMEA AI In Drug Repurposing Market
• 14.8 Key Factors Impacting the Market
  • 14.8.1 Market Drivers
  • 14.8.2 Market Restraints
  • 14.8.3 Market Opportunities
  • 14.8.4 Market Challenges
  • 14.8.5 Market Trends - LAMEA AI In Drug Repurposing Market
  • 14.8.6 State of Competition - LAMEA AI in Drug Repurposing market
  • 14.8.7 LAMEA AI In Drug Repurposing Market by Component
    • 14.8.7.1 LAMEA Software & Platform Market by Country
    • 14.8.7.2 LAMEA Services Market by Country
  • 14.8.8 LAMEA AI In Drug Repurposing Market by Technology
    • 14.8.8.1 LAMEA Machine Learning/Deep Learning Market by Country
    • 14.8.8.2 LAMEA Natural Language Processing (NLP) Market by Country
    • 14.8.8.3 LAMEA Knowledge Graphs & Network-Based AI Market by Country
    • 14.8.8.4 LAMEA Generative AI & Large Language Models (LLMs) Market by Country
    • 14.8.8.5 LAMEA Computer Vision Market by Country
  • 14.8.9 LAMEA AI In Drug Repurposing Market by End Use
    • 14.8.9.1 LAMEA Pharmaceutical & BioTechnology Companies Market by Country
    • 14.8.9.2 LAMEA Contract Research Organizations (CROs) Market by Country
    • 14.8.9.3 LAMEA Academic & Research Institutes Market by Country
    • 14.8.9.4 LAMEA Other End Use Market by Country
  • 14.8.10 LAMEA AI In Drug Repurposing Market by Application
    • 14.8.10.1 LAMEA Oncology Market by Country
    • 14.8.10.2 LAMEA Neurology Market by Country
    • 14.8.10.3 LAMEA Infectious Diseases Market by Country
    • 14.8.10.4 LAMEA Rare & Orphan Diseases Market by Country
    • 14.8.10.5 LAMEA Cardiology Market by Country
    • 14.8.10.6 LAMEA Other Application Market by Country
  • 14.8.11 LAMEA AI In Drug Repurposing Market by Country
    • 14.8.11.1 Brazil AI In Drug Repurposing Market
      • 14.8.11.1.1 Brazil AI In Drug Repurposing Market by Component
      • 14.8.11.1.2 Brazil AI In Drug Repurposing Market by Technology
      • 14.8.11.1.3 Brazil AI In Drug Repurposing Market by End Use
      • 14.8.11.1.4 Brazil AI In Drug Repurposing Market by Application
    • 14.8.11.2 Argentina AI In Drug Repurposing Market
      • 14.8.11.2.1 Argentina AI In Drug Repurposing Market by Component
      • 14.8.11.2.2 Argentina AI In Drug Repurposing Market by Technology
      • 14.8.11.2.3 Argentina AI In Drug Repurposing Market by End Use
      • 14.8.11.2.4 Argentina AI In Drug Repurposing Market by Application
    • 14.8.11.3 UAE AI In Drug Repurposing Market
      • 14.8.11.3.1 UAE AI In Drug Repurposing Market by Component
      • 14.8.11.3.2 UAE AI In Drug Repurposing Market by Technology
      • 14.8.11.3.3 UAE AI In Drug Repurposing Market by End Use
      • 14.8.11.3.4 UAE AI In Drug Repurposing Market by Application
    • 14.8.11.4 Saudi Arabia AI In Drug Repurposing Market
      • 14.8.11.4.1 Saudi Arabia AI In Drug Repurposing Market by Component
      • 14.8.11.4.2 Saudi Arabia AI In Drug Repurposing Market by Technology
      • 14.8.11.4.3 Saudi Arabia AI In Drug Repurposing Market by End Use
      • 14.8.11.4.4 Saudi Arabia AI In Drug Repurposing Market by Application
    • 14.8.11.5 South Africa AI In Drug Repurposing Market
      • 14.8.11.5.1 South Africa AI In Drug Repurposing Market by Component
      • 14.8.11.5.2 South Africa AI In Drug Repurposing Market by Technology
      • 14.8.11.5.3 South Africa AI In Drug Repurposing Market by End Use
      • 14.8.11.5.4 South Africa AI In Drug Repurposing Market by Application
    • 14.8.11.6 Nigeria AI In Drug Repurposing Market
      • 14.8.11.6.1 Nigeria AI In Drug Repurposing Market by Component
      • 14.8.11.6.2 Nigeria AI In Drug Repurposing Market by Technology
      • 14.8.11.6.3 Nigeria AI In Drug Repurposing Market by End Use
      • 14.8.11.6.4 Nigeria AI In Drug Repurposing Market by Application
    • 14.8.11.7 Rest of LAMEA AI In Drug Repurposing Market
      • 14.8.11.7.1 Rest of LAMEA AI In Drug Repurposing Market by Component
      • 14.8.11.7.2 Rest of LAMEA AI In Drug Repurposing Market by Technology
      • 14.8.11.7.3 Rest of LAMEA AI In Drug Repurposing Market by End Use
      • 14.8.11.7.4 Rest of LAMEA AI In Drug Repurposing Market by Application

Chapter 15. Company Profiles

• 15.1 Ginkgo Bioworks Holdings, Inc.
  • 15.1.1 Company Overview
  • 15.1.2 Financial Analysis
  • 15.1.3 Segmental and Regional Analysis
  • 15.1.4 Research & Development Expenses
  • 15.1.5 Recent strategies and developments:
    • 15.1.5.1 Partnerships, Collaborations, and Agreements:
  • 15.1.6 SWOT Analysis
• 15.2 IBM Corporation
  • 15.2.1 Company Overview
  • 15.2.2 Financial Analysis
  • 15.2.3 Regional & Segmental Analysis
  • 15.2.4 Research & Development Expenses
  • 15.2.5 Recent strategies and developments:
    • 15.2.5.1 Partnerships, Collaborations, and Agreements:
  • 15.2.6 SWOT Analysis
• 15.3 Atomwise, Inc.
  • 15.3.1 Company Overview
• 15.4 Cyclica, Inc.
  • 15.4.1 Company Overview
• 15.5 Genesis Healthcare Co.
  • 15.5.1 Company Overview
• 15.6 Verge, Inc.
  • 15.6.1 Company Overview
• 15.7 Novartis AG
  • 15.7.1 Company Overview
  • 15.7.2 Financial Analysis
  • 15.7.3 Segmental and Regional Analysis
  • 15.7.4 Research & Development Expenses
  • 15.7.5 SWOT Analysis
• 15.8 Schrodinger, Inc
  • 15.8.1 Company Overview
  • 15.8.2 Financial Analysis
  • 15.8.3 Segmental and Regional Analysis
  • 15.8.4 Research & Development Expenses
• 15.9 Recursion Pharmaceuticals, Inc.
  • 15.9.1 Company Overview
  • 15.9.2 Financial Analysis
  • 15.9.3 Research & Development Expenses
• 15.10. The Cradle Company
  • 15.10.1 Company Overview

Chapter 16. Winning Imperatives of AI In Drug Repurposing Market